Information for Health Care Providers on Allergies and Anaphylaxis following administration of COVID-19 vaccines

Presenters: Bryna Warshawsky and Catherine Dickson
Q and A: Joseline Zafack

February 10, 2021
Conflicts of interest

- Bryna Warshawsky – no conflicts of interest to declare
- Catherine Dickson– no conflicts of interest to declare
- Joseline Zafack– no conflicts of interest to declare
Objectives

• To outline Canada’s vaccine safety system
• To describe allergy related contraindications or precautions to COVID-19 vaccination
• To describe the features and management of anaphylaxis and other acute events following administration of COVID-19 vaccines
Outline

• Overview of safety monitoring infrastructure in Canada
• Anaphylaxis: definition and mechanism
• Experience with mRNA COVID-19 vaccines in Canada
• Experience with mRNA COVID-19 vaccines in the US
• Possible allergens in mRNA COVID-19 vaccines
• Patients screening and management of history of allergy
• Management of anaphylaxis, fainting and local hives
Overview

Safety is a central consideration for any health product.

- Canada’s rigorous regulatory system ensures that vaccines are safe, effective and of high quality before they are approved, based on clinical trial results and other data submitted to Health Canada.
- No health product is completely risk-free – post-market vaccine surveillance is required to tell us how vaccines are behaving in the entire population and their real-world impact.

Canada’s well-established vaccine surveillance system is a FPT collaboration (e.g., Canadian Immunization Committee, Vaccine Vigilance Working Group) with Health Canada’s regulator, vaccine manufacturers, health care providers, researchers, and the public. It monitors:

1. **Safety** – Does the vaccine cause new, higher frequency or more serious than expected side effects?
2. **Effectiveness** – How well does the vaccine perform in preventing disease transmission and in reducing illness and death?
3. **Coverage** – How many people have been vaccinated and what determines the uptake rate (e.g. vaccine hesitancy, cultural and ethnicity considerations)?

Vaccine safety surveillance

- **rapid detection and action on safety signals**

  **Health Canada** – regulator for quality, safety and efficacy; surveillance; legislative and regulatory tools for compliance and enforcement

  **Public Health Agency of Canada** – surveillance; P/T coordination; NACI secretariat

  **P/Ts** – vaccine program delivery, data collection and reporting adverse events following immunization to PHAC

  **Manufacturers** – submit evidence of safety (also efficacy and quality) to support authorization, monitor product safety post-authorization, report serious adverse events to HC within 15 days and summary safety reports on request, notify HC of any changes to product benefit/risk profile
Canada’s Vaccine Safety Monitoring System

A system built to detect safety signals, alert public health, investigate thoroughly and respond rapidly.

Adverse events following immunization (AEFI)

Adverse reactions are identified during clinical trials and are expected during immunization campaigns, noting new adverse reactions may only be detected when a vaccine is used in real world conditions.

- Vaccine clinical trials may not include groups with different types or higher risk for adverse reactions than the volunteers studied during clinical trials (e.g. people with chronic medical problems).

Types of Adverse Events

Range from minor reactions (e.g. muscle aches, bruising, mild headache, etc) to very rare but serious adverse events (e.g. paralysis, nerve damage).

- An adverse event is a health problem that occurs after vaccination that may or may not be caused by the vaccine – in-depth investigations assess causality.

Post-Market Vaccine Safety Monitoring

HC and PHAC have a well established system to monitor post-market vaccine safety and respond to safety signals in collaboration with provincial and territorial public health authorities.

AEFI – any unfavorable or unintended medical occurrence following immunization, that may or may not have been caused by the vaccine

During pandemic H1N1

12.5 million people vaccinated in Canada

5500 AEFIs reported

460 (8%) serious

Transparent vaccine safety monitoring supports public confidence in immunization programs
**Mechanisms of anaphylaxis**

**IgE-mediated allergic mechanism**

Mature B cells produce specific IgE-antibodies to that allergen. IgE antibodies bind to mast cells and basophils receptors. This initial phase of sensitisation is clinically silent.

On re-exposure, the allergen cross-links two specific IgE receptors, creating a bridge and resulting in mast cell degranulation.

**Release of preformed (e.g. histamine, tryptase) followed by newly formed mediators (e.g. prostaglandin D₂, leukotrienes, thromboxane A₂) results in clinical manifestations of IgE-mediated anaphylaxis.**

**Non-allergic mechanisms**

**Mast cell activation**
- Direct non-specific activation: histamine-releasing agents (usually mild or moderate immediate hypersensitivity)
- Calcium and phospholipase (C and A₂)-dependent mechanism: (e.g. vancomycin and red man syndrome)
- MRGPRX2 activation: NMBAs (remains to be proven in humans)
- Mastocytosis

**Mast cell-independent mechanism**
- COX-1 inhibition: NSAIDs (bronchospasm, angioedema, or both)

**Cofactors that may modulate the onset of allergic and non-allergic immediate hypersensitivity**
- Stress
- Infection
- Dose of allergen
- Rate of drug injection
- Chemical property and molecular weight of drugs
- Host factors
# Signs and symptoms of anaphylaxis

- Sudden onset
- Rapid progression
- ≥ 2 body systems involved

<table>
<thead>
<tr>
<th>System</th>
<th>Signs and symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>General/CNS</td>
<td>Fussiness, irritability, drowsiness, lethargy, reduced level of consciousness, somnolence</td>
</tr>
<tr>
<td>Skin</td>
<td>Urticaria, pruritus, angioedema, flushing</td>
</tr>
<tr>
<td>Upper airway</td>
<td>Stridor, hoarseness, oropharyngeal or laryngeal edema, uvular edema, swollen lips/tongue, sneezing, rhinorrhea, upper airway obstruction</td>
</tr>
<tr>
<td>Lower airway</td>
<td>Coughing, dyspnea, bronchospasm, tachypnea, respiratory arrest</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>Tachycardia, hypotension, dizziness, syncope, arrhythmias, diaphoresis, pallor, cyanosis, cardiac arrest</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>Nausea, vomiting, diarrhea, abdominal pain</td>
</tr>
</tbody>
</table>

Assessment of anaphylaxis cases

- Anaphylaxis cases that are reported to the Canadian Adverse Events Following Immunization Surveillance System (CAEFISS) undergo medical case review and the diagnostic certainty is assessed using the Brighton Collaboration case definition.

ANAPHYLAXIS (Vaccine 2007; 25:5673-84)

<table>
<thead>
<tr>
<th>Table 1</th>
<th>A. COURSE OF ILLNESS</th>
<th>B. MAJOR CRITERIA</th>
<th>C. MINOR CRITERIA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sudden onset of signs and symptoms</td>
<td>Injection site urticaria</td>
<td>Injection site urticaria</td>
</tr>
<tr>
<td></td>
<td>Rapid progression of signs and symptoms</td>
<td>Red AND itchy eyes</td>
<td>Generalized prickle sensation</td>
</tr>
</tbody>
</table>

**Skin**
- Generalized urticaria (hives)
- Generalized erythema
- Angioedema (general or localized)
- Generalized pruritus WITH skin rash

**Resp**
- Bilateral wheeze (by stethoscope)
- Stridor
- ≥ 2 indicators of respiratory distress:
  - Tachypnea
  - Cyanosis
  - Grunting
  - Chest wall retractions
  - ↑ use of accessory muscles

**CV**
- Documented hypotension
- ≥ 3 signs of uncompensated shock
  - Tachycardia
  - Capillary refill >3 seconds
  - Reduced central pulse volume
  - ↓ level or loss of consciousness
- Documented MD diagnosis of shock

**GI**
- Nausea
- Vomiting
- Abdominal pain
- Diarrhea

**LAB**
- Elevated mast cell tryptase

Other relevant info:
- Medical History: □ Chronic disease □ Allergy □ Concomitant med(s)
- Treatment at immunization clinic: □ Epinephrine □ Benadryl □ Other
- Emergency room: Yes No □ Yes □ Epinephrine □ Benadryl □ Other
- Hospitalized: Yes No □ Fully Recovered □ Not yet recovered □ Fatal

Other terms:
- Bilateral red eyes
- Sore throat
- Difficulty swallowing
- Chest tightness
- Rash - generalized
- Rash - localized at non-injection site
- Pallor
- Dizzy
- Metallic taste
- Other (specify)
Assessment of anaphylaxis cases

- Levels I to III are considered anaphylaxis cases.
- Levels IV and V are not considered cases of anaphylaxis

### Levelling Tool: Check all that apply; level=highest row in table with all boxes checked

<table>
<thead>
<tr>
<th>Level</th>
<th>≥ 1 SKIN</th>
<th>≥ 1 RESP</th>
<th>≥ 1 CV</th>
<th>Additional Criteria needed to Meet Level II or III</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>□ MAJOR</td>
<td>□ MAJOR</td>
<td>□ MAJOR</td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ MAJOR</td>
<td>□ MAJOR</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ MAJOR</td>
<td>□ Minor</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ MAJOR</td>
<td>□ Minor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>□ MAJOR</td>
<td>□ MAJOR</td>
<td>□ MAJOR</td>
<td>- ≥1 minor from skin, cardiovascular, gastrointestinal or lab</td>
</tr>
<tr>
<td></td>
<td>□ MAJOR</td>
<td>□ Minor</td>
<td>□ MAJOR</td>
<td>- ≥1 minor skin, respiratory, gastrointestinal or lab</td>
</tr>
<tr>
<td></td>
<td>□ MAJOR</td>
<td>□ Minor</td>
<td>□ Minor</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>□ Minor</td>
<td>□ Minor</td>
<td>□ Minor</td>
<td>- ≥1 minor criterion from at least 2 different systems skin* cardiovascular gastrointestinal lab</td>
</tr>
<tr>
<td></td>
<td>□ Minor</td>
<td>□ Minor</td>
<td>□ Minor</td>
<td>- ≥1 minor criterion from at least 2 different systems skin* respiratory gastrointestinal lab</td>
</tr>
<tr>
<td>IV</td>
<td>Reported anaphylaxis with insufficient evidence to meet case definition levels 1,2 or 3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>V</td>
<td>Not a case of anaphylaxis</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- For level III, a skin MAJOR can count as a minor criterion
Anaphylaxis AEFI reports

- As of January 28, 2021 there were 45 AEFI reports of anaphylaxis submitted to CAEFISS and 915,231 doses administered. This represents a reporting rate of 4.92 per 100,000 doses administered.

- Background rate for anaphylaxis in Canada excluding Quebec, is 8.4 cases per 100,000 people; 95% CI: 8.07-8.74

Data source: Discharge Abstract Database and National Ambulatory Care Reporting System, Canadian Institute for Health Information, fiscal years 2018-2019

Disclaimer for background rate calculations:
- Parts of this material are based on data and information compiled and provided by CIHI. However, the analyses, conclusions, opinions and statements expressed herein are those of the author, and not necessarily those of CIHI.
- The numerator data is from the Discharge Abstract Database (DAD) (acute and non-acute) and the National Ambulatory Care Reporting System (NACRS) with the population estimates from Statistics Canada as the denominator. These rates also allow one individual to contribute more than one event per year.
- Does not include data from Quebec
- Cases of anaphylaxis were identified using all ICD-10CA codes related to anaphylaxis
Anaphylaxis following Pfizer-BioNTech COVID-19 vaccine

- One case of anaphylaxis in clinical trials
- US: 50 cases of anaphylaxis (5.0 per million doses administered)*
- Interval between vaccination and onset of symptoms*:  
  - 74% within 15 minutes  
  - 16% within 15 to 30 minutes  
  - 10% after 30 minutes
- 80% had a documented history of allergies; (24%) had previous anaphylaxis*
- Follow-up (based on 21 patients)**  
  - 19% hospitalized  
  - 81% treated in emergency department  
  - Of 20 with known outcome, all recovered

**https://www.cdc.gov/mmwr/volumes/70/wr/mm7002e1.htm
Anaphylaxis following Moderna COVID-19 vaccine

• No anaphylaxis in clinical trials

• US: 21 cases of anaphylaxis (2.8 per million doses administered)*

• Interval between vaccination and onset of symptoms*:
  – 86% within 15 minutes
  – 4% within 15 to 30 minutes
  – 10% after 30 minutes

• 86% had a documented history of allergy; 24% had previous history of anaphylaxis*

• Follow-up information (based on 10 patients)**
  – 60% hospitalized (5 ICU, 4 intubated)
  – 40% treated in emergency department
  – Of 8 with known outcome, all recovered

**https://www.cdc.gov/mmwr/volumes/70/wr/mm7002e1.htm
## Authorized COVID-19 vaccines

<table>
<thead>
<tr>
<th>Pfizer-BioNTech</th>
<th>Moderna</th>
</tr>
</thead>
<tbody>
<tr>
<td>• nucleoside-modified mRNA encoding the viral spike (S) glycoprotein of SARS-CoV-2</td>
<td>• nucleoside-modified mRNA encoding the viral spike (S) glycoprotein of SARS-CoV-2</td>
</tr>
<tr>
<td>• 2([(\text{polyethylene glycol})-2000]-N,N)-ditetradecylacetamide</td>
<td>• polyethylene glycol (PEG) 2000 DMG</td>
</tr>
<tr>
<td>• 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)</td>
<td>• 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)</td>
</tr>
<tr>
<td>• cholesterol</td>
<td>• cholesterol</td>
</tr>
<tr>
<td>• ALC-0315</td>
<td>• lipid SM-102</td>
</tr>
<tr>
<td>• potassium chloride</td>
<td>• tromethamine</td>
</tr>
<tr>
<td>• monobasic potassium phosphate</td>
<td>• tromethamine hydrochloride</td>
</tr>
<tr>
<td>• sodium chloride</td>
<td>• acetic acid</td>
</tr>
<tr>
<td>• dibasic sodium phosphate dehydrate</td>
<td>• sodium acetate</td>
</tr>
<tr>
<td>• sucrose</td>
<td>• sucrose</td>
</tr>
</tbody>
</table>
## Authorized COVID-19 vaccines

<table>
<thead>
<tr>
<th>Pfizer-BioNTech</th>
<th>Moderna</th>
</tr>
</thead>
<tbody>
<tr>
<td>• nucleoside-modified mRNA encoding the viral spike (S) glycoprotein of SARS-CoV-2</td>
<td>• nucleoside-modified mRNA encoding the viral spike (S) glycoprotein of SARS-CoV-2</td>
</tr>
<tr>
<td>• 2[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide</td>
<td>• polyethylene glycol (PEG) 2000 DMG</td>
</tr>
<tr>
<td>• 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)</td>
<td>• 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)</td>
</tr>
<tr>
<td>• cholesterol</td>
<td>• cholesterol</td>
</tr>
<tr>
<td>• ALC-0315</td>
<td>• lipid SM-102</td>
</tr>
<tr>
<td>• potassium chloride</td>
<td>• tromethamine</td>
</tr>
<tr>
<td>• monobasic potassium phosphate</td>
<td>• tromethamine hydrochloride</td>
</tr>
<tr>
<td>• sodium chloride</td>
<td>• acetic acid</td>
</tr>
<tr>
<td>• dibasic sodium phosphate dehydrate</td>
<td>• sodium acetate</td>
</tr>
<tr>
<td>• sucrose</td>
<td>• sucrose</td>
</tr>
</tbody>
</table>


Polyethylene glycol (PEG)

• Component in several products
  – mRNA COVID-19 vaccines (Pfizer-BioNTech, Moderna)
  – Osmotic laxatives and oral bowel preparations for colonoscopy procedures
  – Excipient in medications

• Rare cause of IgE-mediated reactions
  – patients who have undergone treatment with PEGylated therapeutics can develop antiPEG antibodies
  – PEG-associated anaphylaxis during colonoscopy preparation or laxative use: ~ 4 cases per year in the US

• Potential cross-reactive hypersensitivity between PEG and polysorbates

Stone CA, et al., DOI:10.1016/j.jaip.2018.12.003
Tromethamine (trometamol or tris)

- Component in several products
  - Vaccines (e.g. Moderna COVID-19 vaccine, Act-HiB, Nimenrix)
  - Contrast agents, oral/parenteral medications

- Rare cause of IgE-mediated reactions
  - One case report of anaphylaxis to trometamol (in gadolinium based contrast agents, GBCA)

*CIG, Contents of Immunizing Agents Available for Use in Canada*  
Lukwaska et al, DOI: 10.1016/j.jaip.2018.08.035
Pre-vaccination screening (contraindications)

An authorized COVID-19 vaccines should not be offered routinely to:

- Individuals with a history of severe allergic reaction (e.g. anaphylaxis) after previous administration of either of the authorized COVID-19 vaccines.

- Individuals with a proven severe allergic reaction (e.g. anaphylaxis) to any component of the specific COVID-19 vaccine or its container. For a comprehensive list of components in each authorized COVID-19 vaccine and its container, please consult the corresponding product leaflet or information contained within the product monograph available through [Health Canada's Drug Product Database](https://drugsandallotherproducts.healthcanada.ca/).

Subject to change
Pre-vaccination screening (precautions)

- Individuals with mild to moderate immediate allergic reactions after a previous dose of either mRNA COVID-19 vaccines
  - assessment by a physician or a nurse with expertise in immunization may be warranted prior to re-vaccination
  - 30 minutes of observation post-vaccination, if re-vaccination is chosen

- Individuals with proven severe allergic reaction (e.g. anaphylaxis) to injectable therapy not related to a component of a COVID-19 vaccine
  - do not need to be assessed
  - 30 minutes of observation post-vaccination

*Subject to change*
Not a contraindication nor a precaution

• Individuals with a history of allergy not related to a component of a COVID-19 vaccine or other injectable therapy (e.g. foods, drugs, insect venom or environmental allergens)
  - can receive the COVID-19 vaccines without any special precautions
  - 15 minutes of observation post-vaccination

• All patients should be instructed to seek medical care if they develop signs or symptoms of an allergic reaction after their observation period ends and they have left the immunization clinic/venue

Subject to change
<table>
<thead>
<tr>
<th>Condition</th>
<th>Recommendations</th>
</tr>
</thead>
</table>
| Had a serious or allergic reaction to a previous dose of COVID-19 vaccine | - A known severe allergic reaction (e.g., anaphylaxis) to a past dose of mRNA COVID-19 vaccine is a contraindication to another dose of either mRNA COVID-19 vaccines.  
- Health care provider assessment, with referral as appropriate, is recommended for individuals with less severe allergic reactions that occurred within 4 hours following a previous dose of mRNA COVID-19 vaccine. If the vaccine is given, the individual should be observed for 30 minutes after vaccination. |
| Allergic to polyethylene glycol (PEG)                                    | - A known severe allergy (e.g., anaphylaxis) to PEG is a contraindication to mRNA COVID-19 vaccination.  
- Health care provider assessment, with referral as appropriate, is recommended for individuals with less severe PEG allergy. If the vaccine is given, the individual should be observed for 30 minutes after vaccination. |
| Allergic to tromethamine (trometamol, Tris)                             | People who are allergic to tromethamine can be given the Pfizer-BioNTech vaccine which does not contain tromethamine. |
| Past allergic reaction to another (non-COVID-19) vaccine or other medication given by injection or intravenously | Individuals with past allergic reactions to vaccines or medications given by injection or intravenously (other than as referred to above) should be observed for 30 minutes after receiving an mRNA COVID-19 vaccination. |
| Past allergy but NOT RELATED to any of the above                         | Individuals with past allergic reactions NOT RELATED to mRNA COVID-19 vaccines or its components or other injectable vaccines or therapies (e.g., allergic to foods, oral drugs without PEG or tromethamine, insect venom, pets or environmental allergens) can receive the mRNA COVID-19 vaccines without any special precautions. Individuals should be observed for a minimum of 15 minutes following vaccination. |
Distinguishing anaphylaxis and other events

- Vasovagal syncope (fainting)
- Breath-holding, hyperventilation

<table>
<thead>
<tr>
<th>Clinical features</th>
<th>Anaphylaxis</th>
<th>Vasovagal syncope</th>
</tr>
</thead>
<tbody>
<tr>
<td>Onset from time of immunization</td>
<td>Within minutes up to 4 hours after injection; most within 2 hours</td>
<td>During or within minutes of injection</td>
</tr>
<tr>
<td>Skin</td>
<td>Urticaria, angioedema, pruritus, erythema</td>
<td>Generalized pallor, cold clammy skin</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Cough, wheeze, stridor, respiratory distress, rhinorrhea, sneezing</td>
<td>Normal respiration – may be shallow but not laboured</td>
</tr>
<tr>
<td>Cardiac</td>
<td>Tachycardia</td>
<td>Bradycardia</td>
</tr>
<tr>
<td>Neurologic</td>
<td>Sense of severe anxiety and distress; loss of consciousness – no improvement once supine or in head down position</td>
<td>Sense of light-headedness; loss of consciousness – improves once supine or in head down position; may be transient jerking of the limbs and eye-rolling</td>
</tr>
</tbody>
</table>

Adapted with permission from: Immunisation Section, South Australian Department for Health and Wellbeing.
Fainting

• **Cause:**
  – Anxiety, stress or pain leads to low pulse and blood pressure and subsequent lack of blood flow to the brain

• **Prevention:**
  – Ask clients if they have ever fainted during or after a vaccine or medical procedure
  – Observe for signs of being overly anxious, pale or sweating
  – If any of the above, vaccinate lying down

• **Management:**
  – Lie down on back, turn on side if going to vomit or if pregnant (left side)
  – Raise legs
  – Will come around within a minute or two
  – Continue to monitor until feeling much improved
    • Can offer juice and/or food when better
    • Have someone drive them home
## Management of anaphylaxis (kit)

<table>
<thead>
<tr>
<th>Recommended items</th>
<th>Essential</th>
<th>Optional</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laminated documents</td>
<td>• Clear, concise summary of emergency management protocol</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>• EPINEPHrine dosage by weight and age</td>
<td></td>
</tr>
<tr>
<td>Drugs</td>
<td>EPINEPHrine three vials - 1:1000 (1 mg/mL) solution for IM injection</td>
<td>N/A</td>
</tr>
<tr>
<td>Injection supplies</td>
<td>• Two 1 cc syringes with attached 25 gauge needle (one - 1 inch; one 5/8 inch)</td>
<td>EPINEPHrine autoinjectors labelled by age and weight</td>
</tr>
<tr>
<td></td>
<td>• Three extra 25 gauge needles of each different size: 5/8 inch, 1 or 1.25 inch, 1.5 inch</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>• Scissors</td>
<td>1 nasopharyngeal, 1 oropharyngeal airway for each age range anticipated in the clinic</td>
</tr>
<tr>
<td></td>
<td>• Alcohol swabs</td>
<td>Oxygen and related equipment</td>
</tr>
<tr>
<td></td>
<td>• Tongue depressors</td>
<td>IV lines, fluids and related equipment</td>
</tr>
<tr>
<td></td>
<td>• Pocket mask</td>
<td>Stethoscope</td>
</tr>
<tr>
<td></td>
<td>• Wristwatch with second hand (for heart rate)</td>
<td>Sphygmomanometer</td>
</tr>
<tr>
<td></td>
<td>• Ready access to a phone to call emergency services</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Flashlight</td>
<td></td>
</tr>
</tbody>
</table>

CIG, Anaphylaxis and other Acute Reactions following Vaccination.
Management of anaphylaxis in a community setting

1. **Direct someone to call 911** (where available) or **emergency medical services**.

2. **Assess** airway, breathing, circulation, mental status, skin, and body weight (mass).

3. **Place** individual on his/her back (supine) and elevate lower extremities. Exceptions to the supine position:
   - if in respiratory distress, place in a position of comfort (elevate head and chest)
   - if vomiting or unconscious, place lying on his/her side
   - if pregnant, place lying on their left side

4. **Inject EPINEPHrine**:
   - Dose: 0.01 mg/kg body weight of 1:1000 (1 mg/mL) solution, MAX 0.5 mg (see CIG, Table 4 for dosage by age or weight)
   - Route: IM in mid-antrolateral thigh (*vastus lateralis* muscle)
   - Repeat every 5 minutes if symptoms persist (most patients improve in 1-2 doses)
   - Record the time of each dose

5. **Stabilize and monitor** patient

6. **Transfer to hospital** for observation
Management of hives at the injection site

• Itchy, swollen bumps at the injection site

• Observe for 30 minutes to ensure the hives remain localized

• Can apply ice to the injection site

• If hives disappear and no evidence of spread to other parts of the body and no other symptoms within 30 minutes of vaccination, no further observation needed

• Manage as anaphylaxis if:
  – Any other symptoms arise, even if mild (e.g., sneezing, nasal congestion, tearing, coughing, facial flushing); OR
  – Progression of hives or swelling of the body
Key messages

• Anaphylaxis following mRNA COVID-19 vaccines appears to be more frequent than with other vaccines but is still rare

• Most anaphylactic reactions occur within 15 minutes to 30 minutes after vaccination

• Cause of allergic reaction is not clear; asking about possible allergens can support client management

• Anaphylaxis is a manageable medical emergency
  – Equipment, protocols and training help to ensure good outcomes
NACI Statement on COVID-19 Vaccines

- Refer to NACI recommendations on the use of COVID-19 vaccines for guidance on COVID-19 vaccines.
• Refer to Part 2 - **Vaccine Safety** in the Canadian Immunization Guide (CIG) for definitions of AEFIs and additional general information.

• Guidance on anaphylaxis can be found in the chapter **Anaphylaxis and other Acute Reactions following Vaccination**.
Subscribe for NACI publications and updates to the CIG

Canadian Immunization Guide updates and National Advisory Committee on Immunization - publications mailing list

On this page
- Subscribe
- Cancelling your subscription

Subscribe
To receive information regarding updates to the Canadian Immunization Guide and new National Advisory Committee on Immunization (NACI) recommendations, statements and literature reviews, please enter your e-mail address below and click on the "Subscribe" button.

* Your E-mail address (required)

* Preferred update(s) (required)
- Canadian Immunization Guide
- NACI Recommendations, Statements and Updates
Additional resources

• How to report an AEFI: Reporting Adverse Events Following Immunization (AEFI) in Canada

• Submission of AEFI reports: User guide to completion and submission of the AEFI reports
Acknowledgements

• PHAC Vaccine Safety Section
• National Advisory Committee on Immunization (NACI)
• NACI Vaccine Safety Working Group
Supplementary slides
How AEFIs are detected

Safety signal detection – a shared responsibility between Health Canada, the Public Health Agency of Canada, vaccine manufacturers and the provinces and territories who administer vaccination programs

Safety signal sources

• Signal notification from a province or territory
• HC’s Canada Vigilance Database (CVD) and PHAC’s Canadian Adverse Events Following Immunization Surveillance System (CAEFISS) (weekly)
• International safety notification
• Safety notification from other regulatory agencies
• Safety notification from manufacturer
• Safety summary report from manufacturer
• Published literature review (weekly)
• Media reports

What we look for

• New, unusual, or rare adverse events following immunization (AEFI)
• Increase in AEFI reporting for special events of interest, known and potential AEFIs
• Potential issues with specific vaccine lots
• Potential risk factors related to vaccines
• Potential interactions with other treatments or vaccines
• Unexpected or unusual patterns in the AEFIs reported
How AEFIs are investigated

Who gets notified?
- HC, PHAC, and P/Ts

How are we collaborating?

PHAC
- Collects all available data from CAEFISS and the P/Ts
- Provides information to HC for overall review and regulatory action

HC
- Collects all available data from CVD, CAEFISS and manufacturer
- Conducts overall review for regulatory action
- For urgent or unexpected safety signal (lot related, recall, suspension)
- Engages manufacturer in conducting follow-up assessment
- Considers all available data and conducts review for potential regulatory action
- Can request the manufacturer conduct an assessment

How is risk managed?

- Manufacturer, P/T or HC can recommend hold on vaccine lot
- Issue health professional risk communication
- Issue public advisory
- Advance notification to P/Ts

What are the possible regulatory actions?

- Continue routine monitoring
- Enhanced monitoring
- Update the labelling
- Update the risk management plan
- Suspend/withdraw the product
- Recall the lot and/or the product

Public Health Agency of Canada